Pharming Group N.V. PHARM

AMS: PHARM | ISIN: NL0010391025 12:33

1,118 EUR (-19,89%)

(-19,89%) 12:33

Grafiek Pharming Group N.V.

Grafiek Pharming Group N.V.

1 dag1d -19,89%
1 week1w -21,96%
1 maand1m -21,00%
3 maanden3m -18,85%
6 maanden6m -19,89%
1 jaar1j 46,46%
5 jaar5j 4,15%

donderdag 7 mei 2026, 07:00

Kwartaalcijfers (1ste kwartaal)

Adviezen van analisten

Koersdoel

2,21 EUR

+97,99%

Consensus

Kopen

Verdeling adviezen

Pharming Group N.V. in het nieuws

Toon enkel gratis nieuws

7 mei 2026 · Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 · Persbericht

23 april 2026 · Pharming Group to report first quarter 2026 financial results and provide business update on May 7 · Persbericht

16 april 2026 · Pharming Group announces the 2026 Annual General Meeting of Shareholders · Persbericht

7 april 2026 · Pharming Group to participate in April investor conferences · Persbericht

2 april 2026 · Pharming Group announces the filing of its 2025 Annual Report and Form 20-F · Persbericht

27 maart 2026 · Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older · Persbericht

24 maart 2026 · Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older · Persbericht

12 maart 2026 · Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow · Persbericht

26 februari 2026 · Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12 · Persbericht

17 februari 2026 · Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference · Persbericht

Profiel Pharming Group N.V.

Gezondheidstechnologie

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe